Potential of Lean Body Mass 18F-FDG PET/CT Parameters to Predict Pathologic Findings in Overweight Endometrial Cancer Cases
Open Access
- 4 June 2026
- journal article
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 35 (2) , 105-113
Abstract
Potential of Lean Body Mass 18F-FDG PET/CT Parameters to Predict Pathologic Findings in Overweight Endometrial Cancer Cases - Molecular Imaging and Radionuclide TherapyKeywords
This publication has 19 references indexed in Scilit:
- ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025The Lancet Oncology, 2025
- Abdominal fat distribution in endometrial cancer: from diagnosis to follow-upBMC Cancer, 2025
- Relationship between 18F-fluorodeoxyglucose PET/computed tomography metabolic parameters and clinicopathology in endometrial cancerNuclear Medicine Communications, 2022
- Endometrial cancerThe Lancet, 2022
- Window of opportunity clinical trial designs to study cancer metabolismBritish Journal of Cancer, 2019
- Endometrial Cancer: Obesity, Genetics, and Targeted AgentsObstetrics and Gynecology Clinics of North America, 2019
- Association between 18F-fluorodeoxyglucose-PET/CT and histological grade of uterine endometrial carcinomaTaiwanese Journal of Obstetrics and Gynecology, 2018
- Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of RadiologyRadioGraphics, 2016
- Endometrial cancerThe Lancet, 2016
- Lean body mass correction of standardized uptake value in simultaneous whole-body positron emission tomography and magnetic resonance imagingPhysics in Medicine & Biology, 2015